Warner Bros. pic on top again with a $34.7 mil weekend
"The Dark Knight" proved again over the weekend that it is a major force oversea, finishing with a mighty $34.7 million from 7,754 screens in 62 markets to raise its foreign gross to $382.1 million, more than double the fill for any previous Batman entry.
The Warner Bros. release retained its hold on number one place and -- without serious immediate competition -- is expected to stay on tip for a few more than weeks. ���
With the market slowing down as the summer comes to a close, the big movies of the engaged season ar making final rounds before getting quick for their DVD freeing. Universal's musical hit "Mamma Mia!" raised its weekend voice by $12.8 million for a cume of $234.1 gazillion, while the same studio's "The Mummy: Tomb of the Dragon Emperor" reached an offshore gross of $220 trillion as it registered $12.5 one thousand thousand from 6,000 playdates in 50 countries.
Sony's "You Don't Mess With the Zohan," muscling its way into major abroad markets, brought in $10.4 jillion from 1,985 screens in 30 territories to raise its gross to $56.4 million, patch Disney/Pixar's "WALL-E" kept up its gait as a major contender with a weekend take of $8.5 meg from 3,193 screens in 29 markets for a porcine to engagement of $162.2 gazillion.
Germany brought the Caped Crusader to new high, welcoming the Warner Bros./DC Comics dealership at No. 1 with $9.9 million (including previews) from 955 screens. It took in a 59% portion of the top five films in the territory and exceeded the integral boxoffice take of "Batman Begins" by 17%, Warners said.
In second-weekend "Dark Knight" holds, France stratified No. 1 again with $4.7 million nationwide from 820 screens for a market cume of $16.7 million; Spain slipped to No. 2 with $1.9 one thousand thousand for a market total of $11.7 billion; and Russia held on to the No. 1 spot with $1.7 million for a market score of $6.6 million. Five weeks in the U.K. has delivered $86.1 million; iV in Australia, $40 million; five in Mexico, $24.8 zillion; four in Brazil, $19.3 meg; and three in Korea, $18.6 million.
"Mamma Mia!" had another great weekend in the U.K., according to Universal Pictures International, holding at No. 2 in its seventh weekend and pickings in $3.4 jillion from 501 dates for a market tally of $98.6 million. Meanwhile, "The Mummy" has brought in $12.9 million from Japan; $13.6 million from Germany; and $10.1 million from France. The film is scheduled to open in China, Australia, New Zealand and Italy in September.
"Zohan" opened at No. 1, Spain ($3.4 million from 334 screens) for the biggest Adam Sandler possibility ever in the market. It was 65% better than his previous topper, "Click," and knocked "Dark Knight" out of the No. 1 spot, Sony said.
"WALL-E," which silent has 50% of the international marketplace to go, has taken in $20.2 gazillion from France in four weeks, $12.1 gazillion from Spain in trey and $6.9 one thousand thousand from Korea, also in three. This weekend's openings include India and Denmark.
Among recent newcomers, Ben Stiller's "Tropic Thunder" burst forth with $5 one thousand thousand from eight markets, opening No. 1 in Australia with $2.7 zillion from 224 screens. Fox's "Taken" took in $3.1 billion from 1,069 screens in four-spot markets for a cume of $10.4 billion, and "Mirrors" reflected $1.8 1000000 from 426 screens in 14 territories.
In a typically crowded market, "Hellboy II: The Golden Army" grossed $6.8 million (cume: $32.6 million); "Star Wars: The Clone Wars," $5.1 one thousand thousand (cume: $15.4 1000000); "Get Smart," $4 million (cume: $82.6 jillion); "Kung Fu Panda," $4 million (cume: $372 one thousand thousand); "Wanted," $4 million (cume: $133.2 million); "Meet Dave," $3.7 meg (cume: $27.9 1000000); "The Chronicles of Narnia: Prince Caspian," $3.6 million (cume: $269 trillion); "The Incredible Hulk," $3.4 million (cume: $119.7 zillion); and "Hancock," $1.9 million (cume: $343.1 million).
More information
Wednesday, 27 August 2008
Sunday, 17 August 2008
Download Sondre Lerche mp3
 Artist: Sondre Lerche: mp3 download Genre(s): ROck: Alternative Other Discography:  Phantom Punch Year: 2007 Tracks: 11  Two Way Monologue Year: 2005 Tracks: 12  Faces Down Year: 2002 Tracks: 12 By the time Sondre Lerche had released his major-label debut (2002's critically acclaimed Faces Down), the then 19-year-old Norwegian wunderkind was already a old-timer of the music mankind. Signed to Virgin Norway in 2000, Lerche released the chart-topping EP You Know So Well in February 2001. A commercially successful followup EP, No One's Gonna Come, was released in June of the same year, accompanied by legion local performances and increasing industriousness praise. Lerche's distinctive interpreter and natural natural endowment for authorship likable and alternately cheery and melancholiac start tunes rapidly accomplished him as a definite rival for significance throughout Europe and beyond. Born and raised in Bergen, Norway, Lerche was weaned on the '80s crop up that emanated from his old siblings' rooms. Compelled by a shaping enchantment for bands such as a-ha, the Beach Boys, and Prefab Sprout, Lerche began formal guitar instruction at age eight-spot. Not satisfied with the lessons at school, he experimented with original tunes on his have, finally penning his low gear call, "Locust Girl," at 14. Lerche performed acoustic gigs at the ball club where his baby worked piece he was placid underage, and was "discovered" by Norwegian producer HP Gundersen. Under Gundersen's mentorship, Lerche was exposed to diverse music genres, including psychedelia, '60s pop, and mainstream Brazilian music, broadening his admiration for eclecticist music styles. Around this time Lerche as well met up with Oslo-based manager Tatiana Penzo, in the lead up to a deal with Virgin Norway. The songs from Faces Down had been completed before winter 2000 simply postponed for release until Lerche fulfilled respective academic requirements. In the interim, he was named Best New Act at the Norwegian Grammys (Spellemannprisen) and performed locally in supporting of major acts such as Beth Orton. Faces Down was formally released in Norway in September 2001 and bit by bit end-to-end all of Europe. Lerche toured with versatile acts, including a once-in-a-lifetime opportunity to share the stage with his longtime idols a-ha in Oslo. Autumn 2002 saw the release of Faces Down in America and Lerche's first gear major enlistment of the United States. He tempered fans with the live/studio appeal Don't Be Shallow EP the following year. Lerche got personal for his soph campaign, Two Way Monologue, which appeared in bound 2004. For his adjacent album, Lerche took a stylistic deflection and recorded an album of low-key, jazz-influenced tunes with a minuscule more often than not acoustic version of his Faces Down band. Duper Sessions was released in 2006 and reached number five in the Billboard Top Contemporary Jazz graph. While touring that class with Elvis Costello, Lerche was inspired by Elvis' vigour and interaction with his grouping. This lED Lerche and the Faces Down to record a batch of little, punchy stone songs for 2007's Apparition Punch. Among the fans of Lerche's work was manager Peter Hedges, wHO was looking for individual to furnish music for his 2007 film Dan in Real Life -- soul to be his Cat Stevens (Harold and Maude) or Simon & Garfunkel (The Graduate). He chose Lerche, and the soundtrack featured a mix in of songs from his back catalog and some newly recorded tracks. |
Thursday, 7 August 2008
Beating Depression For Cancer Patients
�A new treatment programme for cancer patients with clinical depression can significantly boost their quality of life according to new research published in the Lancet.
Cancer Research UK scientists devised the treatment programme which offers patients one-to-one sessions with specially trained cancer nurses to help them manage their depression more effectively.
They found that, after three months of receiving the new treatment, almost 20 per cent fewer patients were depressed compared with patients who received standard NHS treatment. The difference was still evident after one year.
The study recruited 200 cancer patients with clinical depression and compared the new strategy - "Depression Care for People with Cancer" - with the standard NHS treatment.
Half were given standard care for depression either from their GP or hospital specialist. The other half received the special programme which entailed sessions on: understanding depression and the effects of antidepressants; problem-solving therapy to help patients overcome feelings of helplessness; liaison with oncologist and GP to collaborate in treatment of depression; monthly monitoring of progress by telephone and providing optional "booster" sessions.
After three months, the patients who were treated in this way found there was an improvement in anxiety and fatigue as well as depression.
Professor Michael Sharpe, from the Psychological Medicine Research group at the University of Edinburgh which carried out the study, said: "Ten per cent of cancer patients experience clinical depression and, unfortunately, it is not always adequately treated. This new treatment could substantially improve the way we manage depression in people with cancer and also in people with other serious medical conditions.
"This is the first time that this type of depression treatment has been evaluated in cancer patients and the results are very encouraging."
Cancer Research UK, which funded the study, has recently awarded Professor Sharpe's research team more than �4 million to continue their work in finding better ways to treat depression and other symptoms in cancer patients.
Dr Lesley Walker, Cancer Research UK's director of cancer information, said: "As well as finding ways to prevent and treat cancer, the charity is committed to improving the quality of life for people who are living with the disease."
About Cancer Research UK
- Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
Cancer Research UK
More info
Cancer Research UK scientists devised the treatment programme which offers patients one-to-one sessions with specially trained cancer nurses to help them manage their depression more effectively.
They found that, after three months of receiving the new treatment, almost 20 per cent fewer patients were depressed compared with patients who received standard NHS treatment. The difference was still evident after one year.
The study recruited 200 cancer patients with clinical depression and compared the new strategy - "Depression Care for People with Cancer" - with the standard NHS treatment.
Half were given standard care for depression either from their GP or hospital specialist. The other half received the special programme which entailed sessions on: understanding depression and the effects of antidepressants; problem-solving therapy to help patients overcome feelings of helplessness; liaison with oncologist and GP to collaborate in treatment of depression; monthly monitoring of progress by telephone and providing optional "booster" sessions.
After three months, the patients who were treated in this way found there was an improvement in anxiety and fatigue as well as depression.
Professor Michael Sharpe, from the Psychological Medicine Research group at the University of Edinburgh which carried out the study, said: "Ten per cent of cancer patients experience clinical depression and, unfortunately, it is not always adequately treated. This new treatment could substantially improve the way we manage depression in people with cancer and also in people with other serious medical conditions.
"This is the first time that this type of depression treatment has been evaluated in cancer patients and the results are very encouraging."
Cancer Research UK, which funded the study, has recently awarded Professor Sharpe's research team more than �4 million to continue their work in finding better ways to treat depression and other symptoms in cancer patients.
Dr Lesley Walker, Cancer Research UK's director of cancer information, said: "As well as finding ways to prevent and treat cancer, the charity is committed to improving the quality of life for people who are living with the disease."
About Cancer Research UK
- Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
Cancer Research UK
More info
Subscribe to:
Posts (Atom)